• OncologyTube
    • 0
      • Title
        User LIVE NOW
      • Logo LIVE NOW
        Title
        User
      • Schedule An Interview
        • Schedule A Remote Interview with OncologyTube
    • Home
    • Trending

    • Sign In

    • Audios and Videos
    • Videos
    • Audios

    • Channels

    • Browse Channels

    • Categories

    • Acute Lymphoblastic Leukemia 5648
    • Acute Myelogenous Leukemia 202
    • Bladder Cancer 71
    • Bone Metastases 2
    • Brain Cancer 59
    • Breast Cancer 233
    • Business Management 3
    • Cervical Cancer 6
    • Chronic Lymphocytic Leukemia 192
    • Chronic Myelogenous Leukemia 43
    • Colorectal Cancer 110
    • COVID-19 27
    • Gastrointestinal Cancer 93
    • General 320
    • Head and Neck Cancers 74
    • Hematologic Malignancies 180
    • Hodgkin Lymphoma 28
    • Immunotherapy 155
    • Kidney Cancer 376
    • Liver Cancer 25
    • Lymphoma 180
    • Melanoma and Skin Cancer 57
    • Multiple Myeloma 466
    • Myeloproliferative Disease 20
    • News 148
    • Non-Hodgkin Lymphoma 77
    • Non-Small Cell Lung Cancer 413
    • Other 256
    • Ovarian Cancer 43
    • Pancreatic Cancer 73
    • Patient Resources 28
    • Pediatric Cancer 3
    • Prostate Cancer 225
    • Sickle Cell 21
    • Small Cell Lung Cancer 72
    • Soft Tissue Sarcoma 10
    • Supportive Care 47
    • Testicular Cancer 3
    • Urology 14
    • Uterine Cancer 7

    • About
    • Contact
    The current treatment landscape for penile cancer
    00:02:37

    The current treatment landscape for penile cancer

    With the involvement of so many genetic and molecular alterations in cancer, it is nearly impossible to know what pathway to target for a clinically significant outcome that also has a low toxicity level. In this interview, Lisa Pickering, MRCP, PhD, of The Royal Marsden NHS Foundation Trust, London, UK, speaking from the Genitourinary Cancers Symposium, in San Francisco, CA, objectively compares retrospective and prospective studies for penile cancer, emphasizing the lack of the prospective studies. She discusses recent trials, including HER-Uro01 (NCT01728233) and the large-scale InPACT study (NCT02305654).

    231 Views
    2 years ago
    VJOncology
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Suggested

    Trending

    The current treatment landscape for penile cancer
    00:02:37

    The current treatment landscape for penile cancer

    Free
    231 Views
    2 years ago
    VJOncology
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Vinflunine shows a chemotherapeutic advantage for locally-advanced and metastatic penile cancer
    00:03:06

    Vinflunine shows a chemotherapeutic advantage for locally-advanced and metastatic penile cancer

    Free
    414 Views
    2 years ago
    VJOncology
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine
    0:05:54

    Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine

    Free
    66 Views
    5 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine - Common Questions Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine - Common Questions
    0:03:31

    Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine - Common Questions

    Free
    10 Views
    5 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    • 1 (current)
    • 2

    Uterine Cancer

    Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine -  Final Thoughts Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine -  Final Thoughts
    0:02:15

    Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine - Final Thoughts

    Free
    22 Views
    5 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine -  What Are The Next Steps Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine -  What Are The Next Steps
    0:02:18

    Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine - What Are The Next Steps

    Free
    25 Views
    5 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine - Will This Affect Clinicians Today Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine - Will This Affect Clinicians Today
    0:02:44

    Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine - Will This Affect Clinicians Today

    Free
    20 Views
    5 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine - Common Questions Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine - Common Questions
    0:03:31

    Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine - Common Questions

    Free
    10 Views
    5 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine
    0:05:54

    Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine

    Free
    66 Views
    5 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    The current treatment landscape for penile cancer
    00:02:37

    The current treatment landscape for penile cancer

    Free
    231 Views
    2 years ago
    VJOncology
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Vinflunine shows a chemotherapeutic advantage for locally-advanced and metastatic penile cancer
    00:03:06

    Vinflunine shows a chemotherapeutic advantage for locally-advanced and metastatic penile cancer

    Free
    414 Views
    2 years ago
    VJOncology
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Copyright 2020 Medicus Networks, Inc. 27574 Commerce Center Drive, Suite 236, Temecula, CA 92592